The alanine scan program identified key residues implicated in the interaction of P60 with FOXP3 and allowed us to define a pharmacophoric model for the identification of a cyclic peptide with improved capacity to inhibit Treg cells in vitro and with anti-tumor activity in vivo. This evidence concerns the gene FOXP3 and neoplasm.